Viloxazine

TRADE NAME: Qelbree (Supernus)
INDICATIONS: Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.
CLASS: Norepinephrine reuptake inhibitor
HALF-LIFE: ~7 hours

FDA APPROVAL DATE: 04/02/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alfentanil, Alosetron, Atomoxetine, Avanafil, Clozapine, Conivaptan, CYP1A2 substrates, CYP2D6 substrates, CYP3A4 substrates, Darunavir, Desipramine, Dextromethorphan, Duloxetine, Everolimus, Ibrutinib, Isocarboxazid, Lomitapide, Lovastatin, Lurasidone, Metoprolol, Midazolam, monoamine oxidase inhibitors, Naloxegol, Nebivolol, Nisoldipine, Nortriptyline, Perphenazine, Phenelzine, Pirfenidone, Ramelteon, Rasagiline, Risperidone, Safinamide, Saquinavir, Selegiline, Simvastatin, Sirolimus, Tacrolimus, Tasimelteon, Theophylline, Tipranavir, Tizanidine, Tolterodine, Tranylcypromine, Triazolam, Vardenafil, Venlafaxine
PREGNANCY: May cause maternal harm; discontinue when pregnancy is recognized.

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

IN CLINICAL TRIALS, HIGHER RATES OF SUICIDAL THOUGHTS AND BEHAVIOR WERE REPORTED IN PEDIATRIC PATIENTS TREATED WITH VILOXAZINE THAN IN PATIENTS TREATED WITH PLACEBO. CLOSELY MONITOR FOR WORSENING AND EMERGENCE OF SUICIDAL THOUGHTS AND BEHAVIORS.

See full prescribing information for complete boxed warning

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Litt's app available free to subscribers

Search drug eruptions and reactions data anytime, anywhere

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

Breast feeding

Geriatric

Pediatric

Viloxazine comment watch save

Viloxazine